In Vitro Efficacy Testing Services for Influenza

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for influenza. Our service offers comprehensive analytical support to evaluate antiviral candidates targeting influenza virus proteins and host-pathogen interactions. Key targets include viral hemagglutinin, neuraminidase, and associated host cell receptors involved in viral entry and replication. We assess mechanisms such as viral binding, inhibition, and immune response modulation to inform therapeutic development for influenza infection.

We offer a range of advanced in vitro testing methods, including biolayer interferometry, ELISA, and surface plasmon resonance assays. These technologies enable precise evaluation of molecular interactions, binding affinities, and inhibitory effects relevant to influenza drug discovery. Our methods are designed to provide quantitative and qualitative data for informed decision-making in the development pipeline.

Biolayer interferometry assay: A label-free technique used to measure real-time binding kinetics between viral proteins and candidate molecules, allowing assessment of interaction strength and specificity.

ELISA assay: A high-throughput immunoassay that quantifies protein-protein or protein-antibody interactions, commonly used to evaluate inhibitory effects of compounds on influenza viral components.

Surface plasmon resonance assay: An optical biosensor approach that provides detailed binding kinetics and affinity data, essential for characterizing the interaction between candidate therapeutics and influenza targets.

We measure key pharmacological parameters such as IC-50 and Kd to characterize antiviral potency and binding affinity. These quantitative metrics are critical for ranking candidate compounds and optimizing lead selection. Accurate parameter determination supports rational drug design and progression through the development process.

IC-50: The half maximal inhibitory concentration, indicating the concentration of a compound required to inhibit a biological process or target by 50%; an essential measure of compound potency.

Kd: The equilibrium dissociation constant, reflecting the affinity between a drug candidate and its target; lower Kd values signify stronger binding, which is crucial for therapeutic efficacy.

Recommended In Vitro Efficacy Tests

Hemagglutinin

Hemagglutinin is a key influenza surface protein mediating viral entry into host cells, making it a prime target in drug development. Hemagglutinin testing assesses drug efficacy and binding, using ELISA, surface plasmon resonance, and biolayer interferometry assays. These methods quantitatively analyze main parameters such as IC-50 (inhibitory concentration) and Kd (binding affinity), providing essential data for optimizing antiviral candidates.

Hemagglutinin (H5)

Hemagglutinin (H5) is a key influenza surface protein mediating viral entry into host cells. Accurate H5 testing is essential for developing effective influenza drugs targeting viral attachment and fusion. Our service uses surface plasmon resonance (SPR) assays to characterize H5 interactions with drug candidates, providing precise binding affinity measurements (Kd). This enables efficient screening and optimization of antiviral compounds targeting H5-driven infection.

Toll Like Receptor 3

Our Toll Like Receptor 3 (TLR3) testing service evaluates TLR3-mediated immune responses in influenza drug development. TLR3 recognizes viral double-stranded RNA, triggering antiviral signaling crucial for host defense. Assessing TLR3 activation helps predict drug efficacy and immunomodulatory effects. Key methods include in vitro cell-based assays and cytokine profiling. Main parameters measured are TLR3 expression, cytokine/chemokine levels (e.g., IFN-β, IL-6), and pathway activation markers.